First Trust Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

First Trust Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Sell	614,206 -142,951	-19%	-$1.96M	0.01%	1193
2026 Q1	$9.41M	Buy	757,157 +116,873	+18%	+$1.57M	0.01%	1124
2025 Q4	$8.07M	Buy	640,284 +20,292	+3%	+$232K	0.01%	1188
2025 Q3	$6.21M	Sell	619,992 -32,745	-5%	-$294K	﹤0.01%	1275
2025 Q2	$5.28M	Buy	652,737 +252,443	+63%	+$1.9M	﹤0.01%	1333
2025 Q1	$3.35M	Sell	400,294 -272,109	-40%	-$2.27M	﹤0.01%	1528
2024 Q4	$5.33M	Buy	672,403 +59,601	+10%	+$500K	﹤0.01%	1326
2024 Q3	$5.1M	Sell	612,802 -16,442	-3%	-$129K	﹤0.01%	1332
2024 Q2	$4M	Buy	+629,244	New	+$3.99M	﹤0.01%	1378
2020 Q3	–	Sell	-221,535	Closed	-$1.05M	–	2308
2020 Q2	$1.05M	Buy	221,535 +16,050	+8%	+$66.1K	﹤0.01%	1715
2020 Q1	$715K	Sell	205,485 -39,169	-16%	-$166K	﹤0.01%	1783
2019 Q4	$1.18M	Sell	244,654 -45,679	-16%	-$159K	﹤0.01%	1817
2019 Q3	$842K	Buy	+290,333	New	+$1.01M	﹤0.01%	1934
2019 Q1	–	Sell	-50,868	Closed	-$688K	–	2406
2018 Q4	$688K	Buy	+50,868	New	+$917K	﹤0.01%	2002

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

First Trust Advisors's AMRX Position: Q2 2026 in Review

First Trust Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 19% in Q2 2026, selling an estimated $1.96M and leaving 614,206 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #1193.

First Trust Advisors first reported a position in AMRX in Q4 2018 and has held it in 14 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

First Trust Advisors held 614,206 shares of Amneal Pharmaceuticals worth $10.6M as of Q2 2026.
First Trust Advisors sold 142,951 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.96M.
Amneal Pharmaceuticals made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1193 holding.
First Trust Advisors first reported a position in Amneal Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.